Meeting Overview

23rd Annual Innovations in Urologic Practice
Santa Fe, New Mexico
September 14-16, 2018

Join Dr. Mohit Khera and many other expert faculty at the beautiful Inn and Spa at Loretto in Santa Fe, New Mexico, to discuss current controversies and innovative diagnostic and treatment strategies for some of the most common urologic diseases. The rapidly changing healthcare environment and pace of technological innovations in medicine require urology professionals to keep up to date on the diagnosis and management of urologic diseases, infections, and genitourinary cancers.


Overview

This CME-accredited conference focuses on current controversies and innovative diagnostic and treatment strategies for some of the most common urologic problems clinical urologists face. The rapidly changing healthcare environment and pace of technological innovations in medicine require urologists to keep abreast of state-of-the-art diagnosis and management of urologic disease.

There have been numerous American Urological Association (AUA) guidelines that have been released in 2017 and 2018, including guidelines on urethral stricture, erectile dysfunction, and testosterone. Practicing urologists need to be aware of practice guidelines to better diagnose and treat urologic conditions.

Needs Statement

This conference focuses on current controversies and innovative diagnostic and treatment strategies for some of the most common urologic problems faced by clinical urologists in the region. The rapidly changing healthcare environment and pace of technological innovations in medicine require urologists to keep abreast of state-of-the-art diagnosis and management of urologic disease.

Target Audience

This activity is designed for specialists in urology and genitourinary cancers.

Educational Objectives

At the conclusion of the activity, participants should be able to:

  • Summarize the most recent American Urological Association guidelines
    for diagnosis and treatment of men with urethral stricture, testosterone
    deficiency, or erectile dysfunction
  • Describe how to use MRI to perform prostate biopsy for the diagnosis of
    prostate cancer
  • Analyze the pros and cons of focal therapy for treatment of prostate cancer
  • Discuss the impact of prescribed testosterone on infertility
  • Evaluate the recent advancements in the treatment of other genitourinary
    cancers, including bladder cancer, RCC, testis cancer, and UTUC
  • Apply the American Urological Association Guidelines in diagnosing
    and treating patients with urethral strictures, testosterone deficiency,
    erectile dysfunction
  • Implement the use of MRI to perform prostate biopsy for the diagnosis
    of prostate cancer

Educational Methods

Lecture ▪ Case Presentations ▪ Question and Answer Session ▪ Panel Discussion

Evaluation

Evaluation by questionnaire will address program content, presentation, and possible bias.

Accreditation/Credit Designation

Baylor College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Baylor College of Medicine designates this live activity for a maximum of 11.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Director

Mohit Khera, MD, MBA, MPH

Associate Professor of Urology
Baylor College of Medicine
Houston, TX

 

Mohit Khera, MD, MBA, MPH, is the Associate Professor of Urology and Director of the Laboratory for Andrology Research at McNair Medical Institute, Baylor College of Medicine. He is also the Medical Director of the Executive Health Program at Baylor. Dr. Khera received his doctorate from The University of Texas Health Science Center at San Antonio, and completed his residency and internship at Baylor. He specializes in male infertility, male and female sexual dysfunction, and declining testosterone levels in aging men. Dr. Khera’s research focuses on the efficacy of botulinum toxin type A in treating Peyronie’s disease as well as genetic and epigenetic studies on post-finasteride syndrome patients and testosterone replacement therapy.